Gainers

• HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million.
• PDS Biotechnology (NASDAQ:PDSB) shares moved upwards by 69.68% to $1.27. The market value of their outstanding shares is at $54.2 million.
• QTREX Quantum (NASDAQ:QTEX) stock increased by 40.45% to $1.54. The company's market cap stands at $73.7 million.
• Apimeds Pharmaceuticals (AMEX:APUS) stock increased by 36.64% to $4.4. The market value of their outstanding shares is at $4.8 million.
• Jaguar Health (NASDAQ:JAGX) shares moved upwards by 33.6% to $4.89. The market value of their outstanding shares is at $1.9 million.
• Vaxcyte (NASDAQ:PCVX) shares moved upwards by 30.48% to $73.7. The market value of their outstanding shares is at $8.4 billion.

Losers

• Stablecoin Development (AMEX:SDEV) shares declined by 50.0% to $3.74 during Monday's regular session. The market value of their outstanding shares is at $202.8 million.
• Sunshine Biopharma (NASDAQ:SBFM) shares declined by 33.88% to $0.44. The company's market cap stands at $2.5 million.
• SeaStar Medical Holding (NASDAQ:ICU) stock decreased by 23.78% to $3.58. The company's market cap stands at $20.6 million.
• Aldeyra Therapeutics (NASDAQ:ALDX) stock fell 22.06% to $0.91. The company's market cap stands at $70.5 million.
• Karyopharm Therapeutics (NASDAQ:KPTI) shares declined by 20.05% to $0.64. The company's market cap stands at $18.1 million.
• Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) stock decreased by 19.18% to $0.1. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.